Harmon Cyrus's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Jun 7, 2023
- Accession no.
- 0001415889-23-009406
- Filed
- Jun 7, 2023
- Trade date
- Jun 5-6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $61.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harmon CyrusCIK 0001831410 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2023 | Common Stock | SSaleDisposed | −5,000 | $6.05 | −$30,250 | 1,053,714 | Direct | |
| Jun 6, 2023 | Common Stock | SSaleDisposed | −5,000 | $6.30 | −$31,500 | 1,048,714 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.